Publication:
Guidelines for the management of hypertension in CKD patients: where do we stand in 2024?

dc.contributor.coauthorTheodorakopoulou, Marieta
dc.contributor.coauthorOrtiz, Alberto
dc.contributor.coauthorFernandez-Fernandez, Beatriz
dc.contributor.coauthorMinutolo, Roberto
dc.contributor.coauthorSarafidis, Pantelis A.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-03-06T20:57:48Z
dc.date.issued2024
dc.description.abstractUntil recently, major bodies producing guidelines for the management of hypertension in patients with chronic kidney disease (CKD) disagreed in some key issues. In June 2023, the European Society of Hypertension (ESH) published the new 2023 ESH Guidelines for the management of arterial hypertension a document that was endorsed by the European Renal Association. Several novel recommendations relevant to the management of hypertension in patients with CKD appeared in these guidelines, which have been updated to reflect the latest evidence-based practices in managing hypertension in CKD patients. Most of these are in general agreement with the previous 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines-some reflect different emphasis on some topics (i.e. detailed algorithms on antihypertensive agent use) while others reflect evolution of important evidence in recent years. The aim of the present review is to summarize and comment on key points and main areas of focus in patients with CKD, as well as to compare and highlight the main differences with the 2021 KDIGO Guidelines for the management of blood pressure in CKD.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThis paper is part of a Supplement that was financially supported by the ERA. The topic of this paper was also presented at the 61st ERA Congress, Stockholm and Virtual, May 23-26, 2024.
dc.identifier.doi10.1093/ckj/sfae278
dc.identifier.eissn2048-8513
dc.identifier.grantnoERA
dc.identifier.issn2048-8505
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85210968861
dc.identifier.urihttps://doi.org/10.1093/ckj/sfae278
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27315
dc.identifier.volume17
dc.identifier.wos1361365200001
dc.keywordsAlbuminuria
dc.keywordsBlood pressure
dc.keywordsChronic kidney disease
dc.keywordsGuidelines
dc.keywordsHypertension
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.ispartofCLINICAL KIDNEY JOURNAL
dc.subjectUrology
dc.subjectNephrology
dc.titleGuidelines for the management of hypertension in CKD patients: where do we stand in 2024?
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorKanbay, Mehmet
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files